- Home
- CDE vs GH Comparison
CDE vs GH Comparison
Compare CDE & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDE | GH |
|---|---|---|
| Founded | 1928 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 13.2B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CDE | GH |
|---|---|---|
| Price | $22.90 | $115.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 21 |
| Target Price | $20.00 | ★ $101.86 |
| AVG Volume (30 Days) | ★ 22.0M | 1.8M |
| Earning Date | 02-18-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $1,700,723,000.00 | $902,569,000.00 |
| Revenue This Year | $95.35 | $35.01 |
| Revenue Next Year | $35.11 | $26.99 |
| P/E Ratio | $31.04 | ★ N/A |
| Revenue Growth | ★ 68.28 | 30.38 |
| 52 Week Low | $4.58 | $34.88 |
| 52 Week High | $23.63 | $116.41 |
Technical Indicators
Market Signals| Indicator | CDE | GH |
|---|---|---|
| Relative Strength Index (RSI) | 73.13 | 68.40 |
| Support Level | $20.17 | $109.11 |
| Resistance Level | $23.74 | $115.54 |
| Average True Range (ATR) | 1.22 | 5.55 |
| MACD | 0.30 | 0.69 |
| Stochastic Oscillator | 88.09 | 93.66 |
Price Performance
Historical ComparisonAbout CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada, and Mexico.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.